Coronary Artery Disease Clinical Trial
— EPIC-CADOfficial title:
A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease
Verified date | June 2024 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months for acute coronary syndrome and ≥ 6 months after stable CAD]) and high-risk atrial fibrillation (CHA2DS2-VASc score ≥2).
Status | Completed |
Enrollment | 1040 |
Est. completion date | November 8, 2023 |
Est. primary completion date | November 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria 1. A subject was = 18 years of age 2. Patients with nonvalvular atrial fibrillation with high embolic risk (CHA2DS2-VASc score =2) 3. Patients with Stable coronary artery disease - Anatomically confirmed coronary artery disease (with =50% stenosis of major epicardial coronary artery documented by cardiac catheterization or coronary computed tomographic angiography) on medical therapy alone. - Revascularized coronary artery disease (either Percutaneous Coronary Intervention or coronary bypass surgery) whom the last revascularization should be performed =12 months before study enrollment for the acute coronary syndrome and =6 months for stable angina pectoris. Exclusion Criteria 1. Patients with thrombocytopenia 2. High risk of bleeding which prohibits the anticoagulant use. (baseline comorbidities, hyper or hypercoagulable state, increased prothrombin time or activated partial thromboplastin time) 3. Prior history of intracranial haemorrhage 4. Mechanical prosthetic valve or moderate to severe mitral stenosis 5. The risk of bleeding increased due to the following reasons; - i. history of gastrointestinal ulcers within 1 month - ii. Malignant tumor with high risk of bleeding - iii. Brain or spinal cord injury within 1 month - iv. History of intracranial or intracerebral hemorrhage within 12 months - v. Esophageal varices - vi. Spinal cord vascular abnormalities or intracerebral vascular abnormalities - vii. Active bleeding - viii. Hemoglobin level <7.0 g/dL or platelet count = 50,000 / mm3 - ix. History of major surgery within 1 month 6. Uncontrolled severe hypertension 7. Hemodynamically Unstable or pulmonary embolism requiring thrombolysis or pulmonary embolectomy 8. History of hypersensitivity to Edoxaban, aspirin, or clopidogrel 9. Genetic problem with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 10. Planned Percutaneous Coronary Intervention or coronary bypass surgery was planned within 1 year after randomization 11. Liver cirrhosis or liver dysfunction (AST or ALT > x3 of normal range or coagulation abnormality) 12. Estimated CrCl by Cockcroft-Gault equation<15 mL/min 13. Life expectancy less than 12 months 14. The subject was unable to provide written informed consent or participate in long-term follow-up 15. Pregnant and/or lactating women 16. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Hallym University Medical Center | Anyang | |
Korea, Republic of | Soon Chun Hyang University Hospital Bucheon | Bucheon | |
Korea, Republic of | Keimyung University Dongsan Medical Center | Daegu | |
Korea, Republic of | Dongguk University Ilsan Hospital | Ilsan | |
Korea, Republic of | Dong-A University Hospital | Pusan | |
Korea, Republic of | Inje University Haeundae Paik Hospital | Pusan | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Kangdong KyungHee University hospital | Seoul | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | The Catholic Univ. of Korea, Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | The Catholic Univ.of Korea Eunpyeong St.Mary's Hospital | Seoul | |
Korea, Republic of | VHS medical center | Seoul | |
Korea, Republic of | The Catholic University of Korea, St. Vincent's Hospital | Suwon | |
Korea, Republic of | Ulsan Univeristy Hospital | Ulsan | |
Korea, Republic of | Pusan National University Yangsan Hospital | Yangsan |
Lead Sponsor | Collaborator |
---|---|
Gi-Byoung Nam | CardioVascular Research Foundation, Korea |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of net Clinical Outcome | composites of death, stroke, systemic embolic event, myocardial infarction, unplanned revascularization of a major coronary artery, major bleeding, and clinically relevant non-major bleeding event | 1 year | |
Secondary | Rate of all cause death | 1 year | ||
Secondary | Rate of cardiovascular death | 1 year | ||
Secondary | Rate of myocardial infarction | 1 year | ||
Secondary | Rate of ischemic stroke | 1 year | ||
Secondary | Rate of systemic embolism | 1 year | ||
Secondary | Rate of unplanned revascularization | 1 year | ||
Secondary | Rate of composite of hard outcomes | all cause death, myocardial infarction, ischemic stroke, and systemic embolism | 1 year | |
Secondary | Rate of stent thrombosis | 1 year | ||
Secondary | Rate of composite of Major or clinically relevant non-major bleeding | Major bleeding
Fatal bleeding Bleeding in the critical site (Intracranial, retroperitoneal, intraocular, intraspinal, intra-articular, pericardial, intramuscular with compartment syndrome) Bleeding causing a fall in haemoglobin level of 2g/dL or leading to transfusion of two or more units of whole blood or red cells. Clinically relevant non-major bleeding defined as any sign or symptom of haemorrhage that does not fit the criteria for The International Society on Thrombosis and Haemostasis (ISTH) major bleeding but requiring medical intervention, leading to hospitalization, or prompting a medical evaluation. Specifically bleeding that meet one of following criteria. bleeding that resulted in hospitalization medical or surgical intervention for bleeding an unscheduled clinic visit, or a change in physician-directed antithrombotic therapy. |
1 year | |
Secondary | Rate of fatal bleeding | International Society on Thrombosis and Haemostasis(ISTH), The Bleeding Academic Research Consortium (BARC)5 | 1 year | |
Secondary | Rate of major bleeding | ISTH, BARC 3, The Thrombolysis in Myocardial Infarction (TIMI) major bleeding | 1 year | |
Secondary | Rate of minor bleeding | ISTH, BARC and TIMI criteria | 1 year | |
Secondary | Rate of intracranial hemorrhage | 1 year | ||
Secondary | Rate of gastrointestinal hemorrhage | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |